Heat shock protein‐70 and hypoxia inducible factor‐1α in type 2 diabetes mellitus patients complicated with retinopathy. (4th January 2016)

• Record Type: Journal Article
• Authors: Sayed, Khulood M.; Mahmoud, Aida A.
• Is Part Of: Acta ophthalmologica. Volume 94:Number 5(2016)
• Page Start: e361
• Page End: e366
• Publication Date: 2016-01-04
• Subjects: diabetic retinopathy -- heat shock protein -- hypoxia inducible factor 1‐α -- Type 2 DM; Ophthalmology -- Periodicals; 617.7005
• DOI: 10.1111/aos.12919
• Languages: English
• ISSNs: 1755-375X

Abstract

Abstract: Purpose: To elucidate the role of heat shock protein‐70 (HSP70) and hypoxia inducible factor‐1 α (HIF‐1 α ) in diabetic retinopathy (DR) patients. Design and methods: A comparative study was done on the serum level of both HSP70 and HIF‐1 α in 50 patients with type 2 diabetes mellitus (T2DM) without DR, 50 patients with T2DM and DR and 70 healthy control subjects. Results: HSP70 and HIF‐1 α were significantly increased in T2DM patients compared to controls and increased in patients with T2DM & DR compared to T2DM patients without DR (p < 0.0001). HSP70 did not differ among the patients with different stages of DR, while HIF‐1 α increased significantly in grades 3 and 4 DR patients compared to grades 1 and 2 DR patients. A strong correlation was found between HIF‐1 α and the development of DR ( r = 0.835, p = 0.00) but not with HSP70. HIF‐1 α can be used as a predictor for development of DR but not HSP70. Conclusions: Our study was the first that investigated both HSP70 and HIF‐1 α in humans and was the first that measured their levels in serum of patients with DR. The study suggested that HSP70 might have a protective function in T2DM patients rather than a therapeutic function. HIF‐1 α had an upper hand in the development and progression of DR. Induction of HSP70 and blockage of HIF‐1 α could lead to the development of novel prophylactic and therapeutic strategies for DR and potentially other diabetic complications.